Hydroxychloroquine (HCQ) Sulfate
别名: NSC 4375
中文名称:硫酸羟氯喹
目录号:S4430 Purity: 99.99%
Hydroxychloroquine (HCQ) Sulfate是一种抗疟疾药,用于治疗系统性红斑狼疮,类风湿关节炎等自身免疫病,炎症以及皮肤病。它也是autophagy和toll-like receptor (TLR) 7/9的抑制剂。
CAS: 747-36-4
客户使用Selleck的Hydroxychloroquine (HCQ) Sulfate发表文献111篇
- Nat Med, 2019 25(4):628-640
- Redox Biol, 2024 75:103274
- Phytomedicine, 2024 10.1016/j.phymed.2023.155152
- Breast Cancer Res, 2024 26(1):33
- PLoS Pathog, 2024 20(1):e1011958
- Commun Biol, 2024 7(1):1581
- Heliyon, 2024 10(11):e32571
- PeerJ, 2024 12:e18227
- Kidney Int, 2023 104(5):943-955
- Nat Commun, 2023 14(1):822
- J Exp Clin Cancer Res, 2023 42(1):204
- Cancer Res, 2023 83(1):141-157
- Pharmacol Res, 2023 197:106955
- JCI Insight, 2023 8(22)e171054
- mBio, 2023 10.1128/mbio.00387-23
- Int J Mol Sci, 2023 24(18)13949
- Int J Mol Med, 2023 52(6)115
- Biomedicines, 2023 11(9)2442
- Oral Dis, 2023 10.1111/odi.14827
- bioRxiv, 2023 2023.01.09.522931
- J Clin Invest, 2022 e153619
- Acta Pharm Sin B, 2022 12(7):3085-3102
- Mol Psychiatry, 2022 none
- Cell Death Dis, 2022 13(3):197
- Cell Rep, 2022 39(3):110712
- Front Immunol, 2022 13:859260
- Int J Mol Sci, 2022 23(24)15747
- Int. J. Mol. Sci, 2022 23(24), 15747
- Neurosci Bull, 2022 10.1007/s12264-022-00818-9
- Front Chem, 2022 10:837987
- Cancers (Basel), 2022 14(19)4690
- Biomedicines, 2022 10(7)1467
- Viruses, 2022 14(9)1887
- Sci Rep, 2022 12(1):11533
- Vet Res, 2022 53-1:62
- PLoS One, 2022 17(11):e0276751
- Autophagy, 2021 1-15
- Autophagy, 2021 1-14
- Cancer Res, 2021 canres.1443.2021
- EMBO Mol Med, 2021 13(9):e13193
- Cancer Lett, 2021 S0304-3835(21)00581-4
- Cell Death Dis, 2021 12(4):347
- Cell Rep, 2021 35(1):108940
- Cell Rep, 2021 35(5):109055
- Bioeng Transl Med, 2021 6(1):e10196
- Gastric Cancer, 2021 10.1007/s10120-021-01250-0
- Front Immunol, 2021 12:645100
- RMD Open, 2021 7(3)e001737
- Front Pharmacol, 2021 12:684243
- Aging (Albany NY), 2021 13(17):21483-21496
- Viruses, 2021 13(7)1227
- Biomedicines, 2021 9(11)1725
- Viruses, 2021 13(2)271
- Sci Rep, 2021 11(1):24005
- Onco Targets Ther, 2021 14:3199-3208
- Toxicol Sci, 2021 kfab079
- PLoS One, 2021 16(6):e0251731
- Mol Med Rep, 2021 24(5)791
- Ann Palliat Med, 2021 10(2):2203-2216
- Eur J Rheumatol, 2021 10.5152/eurjrheum.2021.20054
- Nat Commun, 2020 24;11(1):1985
- Adv Sci (Weinh), 2020 7(22):2002747
- Cell Death Dis, 2020 11(11):991
- Oxid Med Cell Longev, 2020 2020:6096391
- Cancer Gene Ther, 2020 10.1038/s41417-020-0182-y
- Life Sci, 2020 243:117234
- Int Immunopharmacol, 2020 79:106178
- J Cell Physiol, 2020 10.1002/jcp.29433
- Geroscience, 2020 10.1007/s11357-020-00166-4
- Front Microbiol, 2020 10:2936
- Front Oncol, 2020 11;10:217
- Mol Cell Biochem, 2020 470(1-2):175-188
- ACS Omega, 2020 5(33):21231-21240
- bioRxiv, 2020 2020.08.27.270819
- bioRxiv, 2020 2020.08.12.246389
- bioRxiv, 2020 2020.10.02.324228
- BioRxiv, 2020 10.1101/2020.10.29.352450
- Nat Commun, 2019 10(1):2071
- Adv Sci (Weinh), 2019 6(8):1801233
- Cell Death Dis, 2019 10(2):139
- Free Radic Biol Med, 2019 135:87-101
- Int J Cancer, 2019 10.1002/ijc.32615
- J Nutr Biochem, 2019 69:108-119
- J Physiol, 2019 597(6):1585-1603
- Lab Invest, 2019 99(5):625-633
- FASEB J, 2019 10.1096/fj.201900260R
- Cell Signal, 2019 54:17-26
- Cancer Med, 2019 8(2):656-668
- Biomol Ther (Seoul), 2019 27(5):484-491
- Vet Microbiol, 2019 230:283-290
- Platelets, 2019 10.1080/09537104.2019.1609665
- Clin Cancer Res, 2018 10.1158/1078-0432.CCR-18-1489
- J Exp Clin Cancer Res, 2018 37(1):272
- Cell Death Dis, 2018 9(6):604
- Cell Death Dis, 2018 9(2):213
- Front Pharmacol, 2018 9:92
- Front Pharmacol, 2018 9:377
- Int J Mol Med, 2018 42(3):1295-1304
- Drug Des Devel Ther, 2018 12:2655-2663
- J Cell Biochem, 2018 119(7):5921-5933
- J Cancer, 2018 9(18):3247-3256
- Nat Commun, 2017 8:15676
- Cell Death Dis, 2017 8(1):e2558
- Oxid Med Cell Longev, 2017 8519169
- Oncotarget, 2017 8(63):106753-106763
- Oncotarget, 2017 8(4):6608-6622
- Oncotarget, 2017 8(70):114945-114955
- Int J Oncol, 2017 50(5):1810-1820
- Oncol Rep, 2017 38(6):3668-3676
- J Cancer, 2017 8(18):3774-3784
- Onco Targets Ther, 2016 9:6195-6201
化学信息&溶解度
分子量 | 433.95 |
分子式 | C18H28ClN3O5S |
CAS号 | 747-36-4 |
Smiles | CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO.OS(=O)(=O)O |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
Water : 87 mg/mL DMSO : Insoluble ( DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : Insoluble Water : 87 mg/mL DMSO : Insoluble ( DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : Insoluble Water : 87 mg/mL DMSO : Insoluble ( DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : Insoluble Water : 87 mg/mL DMSO : Insoluble ( DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : Insoluble Water : 87 mg/mL DMSO : Insoluble ( DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 |
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。